Celltrion's Covid-19 antibody treatment gets temporary approval in Switzerland

[Photo by Yonhap]

Celltrion’s Covid-19 antibody treatment Regkirona (regdanvimab) has won temporary approval from Swedish health authorities for the treatment of adult patients who do not require supplementary oxygen treatment and are at high risk of developing into severe cases, the company said on Friday. The approval is based on the company’s Phase 3 clinical study that has demonstrated the therapy’s efficacy and safety. It has been administered to treat more than 38,000 Covid-19 patients around the world upon conditional clearance in 13 countries.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]